Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0000950170-25-024116

Options or other derivatives

  • Chief Development Officer acquired 257,500 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Cassella James V Chief Development Officer 2025-02-18 Grant or award · Stock Option (right to buy) +257,500 257,500 D: show line 1 in the form
Loading xslF345X05/ownership.xml…